Viela Bio, Inc.

Amgen, Inc. could more than double the patient base for Uplizna (inebilizumab), currently approved to treat neuromyelitis optica spectrum disorder (NMOSD), with new Phase III data showing the antibod

Amgen, Inc. previously specialized in large therapeutic areas like cardiovascular diseases and inflammation, but added a big focus on medicines for rare diseases through its $27.8bn acquisition of H

ArriVent Biopharma, Inc. launched the second biopharmaceutical company initial public offering of 2024, a day after CG Oncology, Inc. became the first drug developer to go public in the US this yea

Medicines that are awarded orphan drug designations in the EU benefit from a number of rewards, including 10 years of market exclusivity and reduced regulatory fees. However, drugs that are used to tr